Expertise in
6
conditions

Dr. Julia B. Garcia-Diaz

Infectious Disease
Ochsner Clinic Foundation
1514 Jefferson Hwy, 
New Orleans, LA 
Accepting New Patients
Referral may be required
Before you request
Expertise in
6
conditions
Ochsner Clinic Foundation
1514 Jefferson Hwy, 
New Orleans, LA 

Overview

Julia Garcia-Diaz is an Infectious Disease provider practicing medicine in New Orleans, Louisiana.

Dr. Garcia-Diaz is highly rated in 6 conditions, according to our data. Her clinical expertise encompasses HIV/AIDS, Myelitis, AIDS Dementia Complex, and AIDS Dysmorphic Syndrome.

She is actively involved in clinical research, co-authoring 38 peer reviewed articles and participating in 11 clinical trials. Dr. Garcia-Diaz is currently accepting new patients.

Specialties

Infectious Disease

Licenses

Internal Medicine in LA

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO

Locations

Ochsner Clinic Foundation
1514 Jefferson Hwy, New Orleans, LA 70121

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

ACTIV-6: COVID-19 Outpatient Randomized Trial to Evaluate Efficacy of Repurposed Medications
ACTIV-6: COVID-19 Outpatient Randomized Trial to Evaluate Efficacy of Repurposed Medications
Enrollment Status: Completed
Publish Date: November 17, 2025
Intervention Type: Other, Drug
Study Drugs: Ivermectin, Fluvoxamine, Fluticasone
Study Phase: Phase 3
A Phase I/II, Observer-blind, Randomised, Placebo-controlled Study to Assess Safety, Immunogenicity and Efficacy of GSK S. Aureus Candidate Vaccine When Administered to Healthy Adults (Dose-escalation) and to Adults 18 to 64 Years of Age With a Recent S. Aureus Skin and Soft Tissue Infection (SSTI)
A Phase I/II, Observer-blind, Randomised, Placebo-controlled Study to Assess Safety, Immunogenicity and Efficacy of GSK S. Aureus Candidate Vaccine When Administered to Healthy Adults (Dose-escalation) and to Adults 18 to 64 Years of Age With a Recent S. Aureus Skin and Soft Tissue Infection (SSTI)
Enrollment Status: Completed
Publish Date: May 08, 2025
Intervention Type: Biological
Study Phase: Phase 2
A Phase IIIB, Randomized, Observer-blind, Multicenter Study to Assess the Safety and Immunogenicity of GSK's Meningococcal Group B Vaccine When Administered Concomitantly With GSK's Meningococcal MenACWY Conjugate Vaccine to Healthy Subjects of 16-18 Years of Age
A Phase IIIB, Randomized, Observer-blind, Multicenter Study to Assess the Safety and Immunogenicity of GSK's Meningococcal Group B Vaccine When Administered Concomitantly With GSK's Meningococcal MenACWY Conjugate Vaccine to Healthy Subjects of 16-18 Years of Age
Enrollment Status: Completed
Publish Date: March 04, 2025
Intervention Type: Combination product, Biological
Study Phase: Phase 3
A Phase 2 Study to Assess the Effect of a Repeated Dose of XF-73 Nasal Gel on the Microbiological Burden of Commensal Staphylococcus Aureus Nasal Carriage in Surgical Patients at Risk of Post-operative Staphylococcal Infections
A Phase 2 Study to Assess the Effect of a Repeated Dose of XF-73 Nasal Gel on the Microbiological Burden of Commensal Staphylococcus Aureus Nasal Carriage in Surgical Patients at Risk of Post-operative Staphylococcal Infections
Enrollment Status: Completed
Publish Date: October 16, 2023
Intervention Type: Drug
Study Phase: Phase 2
Assessment of Cognitive Ability and the Intestinal Microbiome in Individuals With Liver Disease Before and After Investigational Microbiota Restoration Therapeutic
Assessment of Cognitive Ability and the Intestinal Microbiome in Individuals With Liver Disease Before and After Investigational Microbiota Restoration Therapeutic
Enrollment Status: Terminated
Publish Date: October 03, 2023
Intervention Type: Biological
Study Drug: RBX7455
Study Phase: Phase 2
Randomized Master Protocol for Immune Modulators for Treating COVID-19
Randomized Master Protocol for Immune Modulators for Treating COVID-19
Enrollment Status: Completed
Publish Date: September 25, 2023
Intervention Type: Drug
Study Drugs: Infliximab, Abatacept, Remdesivir, Cenicriviroc
Study Phase: Phase 3
CONSORTIUM - A Double-Blind Placebo-Controlled Phase 2 Study of VE303 for Prevention of Recurrent Clostridium (Clostridioides) Difficile Infection
CONSORTIUM - A Double-Blind Placebo-Controlled Phase 2 Study of VE303 for Prevention of Recurrent Clostridium (Clostridioides) Difficile Infection
Enrollment Status: Completed
Publish Date: July 03, 2023
Intervention Type: Drug
Study Phase: Phase 2
Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of the Effect of Anti-CD14 Treatment in Hospitalized Patients With COVID-19
Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of the Effect of Anti-CD14 Treatment in Hospitalized Patients With COVID-19
Enrollment Status: Terminated
Publish Date: June 26, 2023
Intervention Type: Other, Drug, Biological
Study Drugs: Anti-CD14, Remdesivir
Study Phase: Phase 2
A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of TJ003234 in Subjects With Severe Coronavirus Disease 2019 (COVID-19)
A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of TJ003234 in Subjects With Severe Coronavirus Disease 2019 (COVID-19)
Enrollment Status: Completed
Publish Date: May 06, 2023
Intervention Type: Drug
Study Drug: TJ003234
Study Phase: Phase 2/Phase 3
A Phase 3, Multicenter, Randomized, Open-label, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment With Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir
A Phase 3, Multicenter, Randomized, Open-label, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment With Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir
Enrollment Status: Completed
Publish Date: November 03, 2021
Intervention Type: Drug
Study Phase: Phase 3
View 9 Less Clinical Trials

38 Total Publications

Escherichia coli ST131 Drives Carbapenem Use for E. coli Bloodstream Infections.
Escherichia coli ST131 Drives Carbapenem Use for E. coli Bloodstream Infections.
Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: August 07, 2025
Similar Doctors
Expertise in
4
conditions
Dr. David H. Martin
Infectious Disease
Expertise in
4
conditions
Dr. David H. Martin
Infectious Disease
Referral may be required

Office

1542 Tulane Ave, 
New Orleans, LA 
 (4.0 miles away)
504-599-1457
Languages Spoken:
English
See accepted insurances

David Martin is an Infectious Disease provider practicing medicine in New Orleans, Louisiana. Dr. Martin is highly rated in 4 conditions, according to our data. His clinical expertise encompasses Urethritis, Chlamydia, Trichomoniasis, and Gonorrhea.

Expertise in
6
conditions
Dr. Rebecca A. Lillis
Infectious Disease
Expertise in
6
conditions
Dr. Rebecca A. Lillis
Infectious Disease
Referral may be required

University Medical Center

2000 Canal St, 
New Orleans, LA 
 (3.9 miles away)
504-702-5700
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Rebecca Lillis is an Infectious Disease provider practicing medicine in New Orleans, Louisiana. Dr. Lillis is highly rated in 6 conditions, according to our data. Her clinical expertise encompasses Gonorrhea, Chlamydia, Trichomoniasis, and Urethritis. Dr. Lillis is currently accepting new patients.

Expertise in
5
conditions
Dr. Michael E. Hagensee
Infectious Disease
Expertise in
5
conditions
Dr. Michael E. Hagensee
Infectious Disease
Referral may be required

Ochsner Medical Center - New Orleans

1514 Jefferson Hwy, 
New Orleans, LA 
 (0.1 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Michael Hagensee is an Infectious Disease provider practicing medicine in New Orleans, Louisiana. Dr. Hagensee is highly rated in 5 conditions, according to our data. His clinical expertise encompasses HIV/AIDS, Myelitis, AIDS Dysmorphic Syndrome, and AIDS Dementia Complex. Dr. Hagensee is board certified in American Board Of Internal Medicine - Infectious Disease. Dr. Hagensee is currently accepting new patients.

Frequently Asked Questions about Dr. Julia B. Garcia-Diaz

How do I make an appointment with Dr. Julia B. Garcia-Diaz?

You can book an appointment with Dr. Julia B. Garcia-Diaz by calling their office at 504-842-4005. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Julia B. Garcia-Diaz a top-rated expert for HIV/AIDS?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Julia B. Garcia-Diaz is classified as an Advanced expert for HIV/AIDS, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Julia B. Garcia-Diaz specialize in?

While Dr. Julia B. Garcia-Diaz is a Infectious Disease, they have specific expertise in HIV/AIDS, Myelitis, and AIDS Dementia Complex. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Infectious Disease.

Does Dr. Julia B. Garcia-Diaz participate in research or clinical trials?

Yes. Dr. Julia B. Garcia-Diaz has published 38 articles and abstracts on conditions like HIV/AIDS. You can view a list of Dr. Julia B. Garcia-Diaz's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Julia B. Garcia-Diaz accept my insurance?

Dr. Julia B. Garcia-Diaz accepts most major insurance plans, including Blue Cross Blue Shield and Humana. We recommend calling the office directly at 504-842-4005 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Garcia-Diaz's expertise for a condition
ConditionClose
      View All 19 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile